These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 38281298)

  • 1. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    Zhang H; Lin J; Yahaya BH
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
    Feng W; He Z; Shi L; Zhu Z; Ma H
    Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
    Huang D; Tang E; Zhang T; Xu G
    Front Immunol; 2022; 13():916284. PubMed ID: 35860256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic and immunogenomic analysis of three prognostic signature genes in LUAD.
    Feng HM; Zhao Y; Yan WJ; Li B
    BMC Bioinformatics; 2023 Jan; 24(1):19. PubMed ID: 36650426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
    Wang J; Shu J
    Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
    Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
    Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
    Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
    Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
    Li F; Niu Y; Zhao W; Yan C; Qi Y
    Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
    Zhang J; Song L; Li G; Liang A; Cai X; Huang Y; Zhu X; Zhou X
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17199-17213. PubMed ID: 37789154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes.
    Zhang Y; Qin W; Zhang W; Qin Y; Zhou YL
    Clin Transl Oncol; 2023 Apr; 25(4):959-975. PubMed ID: 36447119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Prediction Value and Biological Functions of Non-Apoptotic Regulated Cell Death Genes in Lung Adenocarcinoma.
    Li HL; Wang JX; Dai HW; Liu JJ; Liu ZY; Zou MY; Zhang L; Wang WR
    Chin Med Sci J; 2023 Sep; 38(3):178-190. PubMed ID: 37622313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma.
    Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P
    Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.